At the end of each month Chimera Research Group provides you with a monthly summary of ten notable catalysts/events that have been completed during the past month. APRIL 2015: Gilead Sciences (NASDAQ: GILD) exceeded analyst expectations reporting $7.6 billion in first quarter revenue , including $4.55 billion from their HCV portfolio of Harvoni and Sovaldi. Revenue […]
Chimera Research Group Catalyst Summary for March 2015
At the end of each month Chimera Research Group provides you with a monthly summary of TEN notable catalysts/events that have occurred during the past month. MARCH 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY) announced that the FDA approved the expanded use of Opdivo to treat patients with advanced squamous non-small cell lung cancer (NSCLC). Approval came just over two […]
Chimera Research Group Catalyst Summary for February 2015
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. February 2015: GILD provided detailed results of their Phase 3 once-daily single tablet regimen of tenofovir alafenamide (TAF) for the treatment of HIV-1 infection. The data showed that it was found […]
Chimera Research Group Catalyst Summary for January 2015
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. JANUARY 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY) announced that their Phase 3 CheckMate-017 trial evaluating Opdivo versus docetaxel for the treatment of refractory squamous cell non-small cell lung cancer […]
Chimera Research Group Catalyst Summary for December 2014
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. DECEMBER 2014: 1) AbbVie (NYSE:ABBV) announced that the FDA approved Viekira Pak (ombitasvir/paritaprevir/ritonavir & dasabuvir), their next generation oral treatment for patients with chronic genotype 1 (GT1) hepatitis C […]
